Cumberland Pharmaceuticals Files 8-K
Ticker: CPIX · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1087294
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: CPRX
TL;DR
CPRX filed an 8-K on March 5th for financial updates.
AI Summary
Cumberland Pharmaceuticals Inc. filed an 8-K on March 5, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This filing signifies a formal update from Cumberland Pharmaceuticals Inc. to the SEC regarding its financial status and operations, which is crucial for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not inherently present new risks.
Key Players & Entities
- CUMBERLAND PHARMACEUTICALS INC. (company) — Registrant
- 0001628280-24-009006 (filing_id) — Accession Number
- March 5, 2024 (date) — Report Date
- 2525 WEST END AVENUE, SUITE 950 (address) — Principal Executive Offices
- Nashville, Tennessee (location) — Principal Executive Offices Location
FAQ
What is the purpose of this 8-K filing?
The purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Cumberland Pharmaceuticals Inc., and to file Financial Statements and Exhibits.
When was this 8-K filed?
This 8-K was filed on March 5, 2024.
What is the company's full name?
The company's full name is CUMBERLAND PHARMACEUTICALS INC.
Where are Cumberland Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at 2525 West End Avenue, Suite 950, Nashville, Tennessee 37203.
What is the SIC code for Cumberland Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Cumberland Pharmaceuticals Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 528 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-05 17:10:30
Filing Documents
- cpix-20240305.htm (8-K) — 27KB
- a2023q4ex991earningsrelease.htm (EX-99.1) — 267KB
- image_0.jpg (GRAPHIC) — 23KB
- 0001628280-24-009006.txt ( ) — 476KB
- cpix-20240305.xsd (EX-101.SCH) — 2KB
- cpix-20240305_lab.xml (EX-101.LAB) — 24KB
- cpix-20240305_pre.xml (EX-101.PRE) — 12KB
- cpix-20240305_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 5, 2024, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release which provided a company update and the financial results for the three months and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. This information is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless specifically incorporated by reference in a document filed under the Securities Act of 1933, as amended, or the Exchange Act. By filing this report on Form 8-K and furnishing this information, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by Item 2.02.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release dated March 5, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cumberland Pharmaceuticals Inc. Dated: March 5, 2024 By: /s/ John Hamm John Hamm Chief Financial Officer